JG
ALXN

Jefferies Group’s Alexion Pharmaceuticals ALXN Stock Holding History

Jefferies Group’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-83,000
Closed -$9.5M – 1895
2020
Q3 		$9.5M Buy
+83,000
New +$8.95M 0.11% 154
2020
Q2 		– Sell
-30,400
Closed -$2.65M – 2240
2020
Q1 		$2.65M Buy
30,400
+21,800
+253% +$2.14M 0.03% 540
2019
Q4 		$930K Sell
8,600
-10,000
-54% -$1.07M 0.01% 1505
2019
Q3 		$1.82M Buy
18,600
+13,300
+251% +$1.5M 0.01% 1147
2019
Q2 		$694K Buy
5,300
+300
+6% +$38.7K 0.01% 1492
2019
Q1 		$676K Sell
5,000
-73,300
-94% -$9.11M 0.01% 1457
2018
Q4 		$7.62M Buy
+78,300
New +$9.26M 0.06% 258
2018
Q3 		– Sell
-62,600
Closed -$7.77M – 2864
2018
Q2 		$7.77M Buy
+62,600
New +$7.32M 0.04% 334
2016
Q1 		– Sell
-6,200
Closed -$1.18M – 2686
2015
Q4 		$1.18M Sell
6,200
-6,600
-52% -$1.15M 0.01% 1103
2015
Q3 		$2M Buy
+12,800
New +$2.33M 0.01% 892
2014
Q1 		– Sell
-40,200
Closed -$5.34M – 2472
2013
Q4 		$5.34M Sell
40,200
-59,600
-60% -$7.15M 0.03% 300
2013
Q3 		$11.6M Sell
99,800
-171,100
-63% -$18.8M 0.11% 151
2013
Q2 		$25M Buy
+270,900
New +$26.1M 0.27% 51

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Jefferies Group's ALXN Position: Q3 2021 in Review

Jefferies Group sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 57,500 shares — an estimated $10.6M sold.

Jefferies Group first reported a position in ALXN in Q2 2013 and held it in 27 quarters. The position peaked at $13.4M in Q4 2020. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Jefferies Group reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Jefferies Group sold 57,500 Alexion Pharmaceuticals shares in Q3 2021, an estimated $10.6M.
  • Jefferies Group first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 27 quarters.
  • Jefferies Group's Alexion Pharmaceuticals position peaked at $13.4M in Q4 2020.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Jefferies Group's 13F filing for Q3 2021, filed 15 Nov 2021.